LLY
Eli Lilly and Company
LLY has the edge over MGNX overall, supported by stronger fundamentals and lower modeled downside.
MGNX
MacroGenics, Inc.
MGNX trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
MGNX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Under pressure | |
| Unavailable |
MGNX's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
MGNX PE Valuation
MGNX has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
MGNX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect MGNX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over MGNX on earnings quality, reporting a profit while its opponent remains loss making.
MGNX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.82 | +$0.37 |
| Q2 2026 | -$0.23 | +$0.33 |
| Q1 2026 | -$1.11 | -$0.23 |
| Q4 2025 | -$1.18 | -$0.11 |
| Q3 2025 | -$1.19 | +$0.38 |
| Q2 2025 | -$0.56 | +$1.63 |
| Q1 2025 | -$0.88 | -$0.50 |
| Q4 2024 | -$1.07 | -$0.92 |
MGNX is still losing money, but far less than before: $0.82 per share over the past year, against $3.56 at its worst in mid-2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over MGNX on profitability, with a higher operating margin.
MGNX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.7M | -74% |
| Q2 2026 | $32.8M | +48% |
| Q1 2026 | $20.8M | +57% |
| Q4 2025 | $41.2M | +113% |
| Q3 2025 | $72.8M | -34% |
| Q2 2025 | $22.2M | +106% |
| Q1 2025 | $13.2M | +45% |
| Q4 2024 | $19.4M | +81% |
MGNX's revenue has slid since its 2024 peak: $19M last quarter, down 74% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -109% | -134 points |
| Q2 2026 | -42% | +123 points |
| Q1 2026 | -161% | +162 points |
| Q4 2025 | -29% | +244 points |
| Q3 2025 | 26% | -23 points |
| Q2 2025 | -165% | +374 points |
| Q1 2025 | -323% | +267 points |
| Q4 2024 | -273% | +187 points |
MGNX's operating margin was −109% last quarter, down 134 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over MGNX on cash generation, producing positive trailing cash flow while its opponent burns cash.
MGNX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.4M | +$24.2M |
| Q2 2026 | -$41.6M | +$6.1M |
| Q1 2026 | -$36.2M | +$11.3M |
| Q4 2025 | $42.8M | +$81.8M |
| Q3 2025 | -$30.6M | -151% |
| Q2 2025 | -$47.7M | -$2.2M |
| Q1 2025 | -$47.4M | -$317K |
| Q4 2024 | -$39M | -$10.4M |
MGNX has burned cash in almost every quarter: −$41M over the past year, against −$165M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over MGNX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
MGNX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +149K shares |
| 1 year | +0.7% | +460K shares |
| 3 years | +2.4% | +1.5M shares |
| 5 years | +4.2% | +2.6M shares |
| Available history | +33% | +15.7M shares |
MGNX has 64M diluted shares, up 0.7% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
MGNX Net Leverage
MGNX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
MGNX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.1 | Neutral |
| Stochastic | 16.0 | Oversold |
MGNX's weekly RSI is 35 (neutral) and its Stochastic is 16 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
MGNX PE vs Healthcare Sector
| Metric | MGNX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MGNX has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over MGNX on trend strength, trading above more of its moving averages.
MGNX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.95 | 22% below |
| 20 week MA | $3.68 | 38% below |
| 50 week MA | $3.11 | 26% below |
| 100 week MA | $2.51 | 8.8% below |
| 200 week MA | $4.78 | 52% below |
MGNX is in a downtrend: it's below all five of its weekly moving averages, and 52% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
MGNX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.8 | $24.3 | +126% |
| 2021 | $24.3 | $17.4 | -28% |
| 2022 | $17.4 | $5.94 | -66% |
| 2023 | $5.94 | $9.62 | +62% |
| 2024 | $9.62 | $3.23 | -66% |
| 2025 | $3.23 | $1.61 | -50% |
| 2026 YTD | $1.61 | $2.29 | +42% |
MGNX has the edge over LLY on returns for 2026, with the stronger performance.